276 reports of this reaction
1.7% of all BUPRENORPHINE HYDROCHLORIDE reports
#8 most reported adverse reaction
PRODUCT ADHESION ISSUE is the #8 most commonly reported adverse reaction for BUPRENORPHINE HYDROCHLORIDE, manufactured by BioDelivery Sciences International Inc. There are 276 FDA adverse event reports linking BUPRENORPHINE HYDROCHLORIDE to PRODUCT ADHESION ISSUE. This represents approximately 1.7% of all 15,869 adverse event reports for this drug.
Patients taking BUPRENORPHINE HYDROCHLORIDE who experience product adhesion issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT ADHESION ISSUE is a less commonly reported adverse event for BUPRENORPHINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to product adhesion issue, the following adverse reactions have been reported for BUPRENORPHINE HYDROCHLORIDE:
The following drugs have also been linked to product adhesion issue in FDA adverse event reports:
PRODUCT ADHESION ISSUE has been reported as an adverse event in 276 FDA reports for BUPRENORPHINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT ADHESION ISSUE accounts for approximately 1.7% of all adverse event reports for BUPRENORPHINE HYDROCHLORIDE, making it a notable side effect.
If you experience product adhesion issue while taking BUPRENORPHINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.